bnb-logo.jpg
askbio.png

Brain Neurotherapy Bio, Inc (BNB) is pleased to announce its recent merger with Asklepios BioPharmaceutical, Inc (AskBio), a Bayer company pioneering research, development and manufacturing of gene therapies across a broad range of therapeutic indications.  As an integrated unit of AskBio, Brain Neurotherapy Bio will continue to lead the development of gene therapies for patients living with neurodegenerative diseases, including ongoing clinical stage glial cell line-derived neurotrophic factor (GDNF) gene therapy programs for Parkinson’s disease (https://clinicaltrials.gov/ct2/show/NCT04167540) and Multiple System Atrophy. Access to AskBio’s proprietary and industry-leading adeno-associated virus (AAV)-based gene therapy manufacturing infrastructure is a critical element for our therapeutic programs. Brain Neurotherapy Bio’s founder, Dr Krystof Bankiewicz, and colleagues look forward to working with the AskBio team to accelerate the development of advanced genetic therapies for a broad range of neurological diseases and genetic disorders.